<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Antiphospholipid-Syndrome on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/antiphospholipid-syndrome/</link><description>Recent content in Antiphospholipid-Syndrome on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Tue, 10 Nov 2026 05:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/antiphospholipid-syndrome/index.xml" rel="self" type="application/rss+xml"/><item><title>Hepatic Control of Immunometabolism in ARDs</title><link>https://rheumatologydigest.org/posts/hepatic-control-of-immunometabolism/</link><pubDate>Tue, 10 Nov 2026 05:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/hepatic-control-of-immunometabolism/</guid><description>Liver oxidative stress and loss of PON1 may start lupus and APS. Much is mouse data; the practical parts are liver tests, biopsy triggers and MASLD.</description></item><item><title>APS Epidemiology in the Evolving Criteria Era</title><link>https://rheumatologydigest.org/posts/aps-epidemiology-evolving-criteria/</link><pubDate>Mon, 02 Nov 2026 04:30:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/aps-epidemiology-evolving-criteria/</guid><description>A single positive aPL test is common, persistent high-titre positivity is rare, and APS estimates shift with the definition, including the 2023 criteria.</description></item></channel></rss>